Ligand Pharmaceuticals Inc.  

(Public, NASDAQ:LGND)   Watch this stock  
Find more results for LGND
108.74
+0.48 (0.44%)
After Hours: 109.99 +1.25 (1.15%)
Aug 3, 7:50PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 107.89 - 108.95
52 week 41.99 - 109.95
Open 108.62
Vol / Avg. 251,553.00/378,738.00
Mkt cap 2.13B
P/E 211.55
Div/yield     -
EPS 0.51
Shares 19.67M
Beta 0.91
Inst. own 113%
Aug 4, 2015
Q2 2015 Ligand Pharmaceuticals Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 4, 2015
Q2 2015 Ligand Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Jul 8, 2015
Ligand Pharmaceuticals Inc at Cantor Fitzgerald Inaugural Healthcare Conference
Jun 24, 2015
Ligand Pharmaceuticals Inc at JMP Securities Life Sciences Conference
Jun 24, 2015
Ligand Pharmaceuticals Inc at ROTH Healthcare Day - London
Jun 7, 2015
Ligand Pharmaceuticals Inc LGD-6972 Phase 1b Data at American Diabetes Association 75th Scientific Sessions
May 12, 2015
Ligand Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 11, 2015
Q1 2015 Ligand Pharmaceuticals Inc Earnings Release
May 11, 2015
Q1 2015 Ligand Pharmaceuticals Inc Earnings Call
May 6, 2015
Ligand Pharmaceuticals Inc at Deutsche Bank Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -0.61% 16.88%
Operating margin 22.94% 30.41%
EBITD margin - 36.27%
Return on average assets -0.14% 6.01%
Return on average equity 9.84% 31.67%
Employees 19 -
CDP Score - -

Address

Suite 200, 11119 North Torrey Pines Road
LA JOLLA, CA 92037
United States - Map
+1-858-5507500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ligand Pharmaceuticals Incorporated (Ligand) is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Company's technology CAPTISOL is a formulation technology that has enabled seven United States Food and Drug Administration (FDA) approved products including Kyprolis and Noxafil-IV and is being developed in several clinical-stage partner programs. The Company is engaged in the development of product candidates indicated for the treatment of diseases, such as hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis (FSGS) and osteoporosis.

Officers and directors

John W. Kozarich Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Matthew W. Foehr President, Chief Operating Officer
Age: 42
Bio & Compensation  - Reuters
John L. Higgins Chief Executive Officer, Director
Bio & Compensation  - Reuters
Melanie Herman Interim Chief Financial Officer
Age: 36
Bio & Compensation  - Reuters
Charles S. Berkman J.D. Vice President, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Jason M. Aryeh Independent Director
Age: 46
Bio & Compensation  - Reuters
Todd C. Davis Independent Director
Age: 54
Bio & Compensation  - Reuters
David M. Knott Independent Director
Age: 70
Bio & Compensation  - Reuters
John L. LaMattina Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Sunil Patel Independent Director
Age: 43
Bio & Compensation  - Reuters